Vertex Pharmaceuticals (VRTX) Minority Interest (2011 - 2018)

Vertex Pharmaceuticals' Minority Interest history runs 8 years deep, the most recent figure standing at $28.4 million for Q3 2018.

• On a quarterly basis, Minority Interest rose 133.13% year-over-year to $28.4 million in Q3 2018; TTM through Sep 2018 was $28.4 million, a 133.13% increase from a year earlier, with the FY2017 full-year figure at $13.7 million, down 92.44% from the prior year.
• Minority Interest declined to $28.4 million in Q3 2018 per VRTX's latest filing, from $28.7 million in the prior quarter.
• Across five years, Minority Interest topped out at $196.0 million in Q2 2017 and bottomed at $12.2 million in Q3 2017.
• The 5-year median for Minority Interest is $153.5 million (2015), against an average of $106.9 million.
• Across the five-year window, Minority Interest surged 654.87% in 2016 and plunged 93.49% in 2017, its largest moves.
• Year by year, Minority Interest stood at $21.2 million in 2014, then soared by 625.6% to $153.7 million in 2015, then advanced by 18.19% to $181.6 million in 2016, then tumbled by 92.44% to $13.7 million in 2017, then soared by 106.64% to $28.4 million in 2018.
• Per Business Quant, the three latest VRTX Minority Interest figures stand at $28.4 million (Q3 2018), $28.7 million (Q2 2018), and $29.8 million (Q1 2018).